Minerva Neurosciences, Inc. (NERV): David Kupfer , director of Minerva Neurosciences, Inc. purchased 55,635 shares on Jun 20, 2016. The Insider buying transaction was reported by the company on Jun 21, 2016 to the Securities and Exchange Commission. The shares were purchased at $10.84 per share for a total value of $603,001.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 18, 2016, David Kupfer (director) purchased 181,488 shares at $5.51 per share price.On Mar 20, 2015, Michele Ollier (director 10% owner) purchased 202,634 shares at $4.81 per share price.Also, On Mar 20, 2015, Rubertis Francesco De (director 10% owner) purchased 202,634 shares at $4.81 per share price.
Minerva Neurosciences Inc: On Monday, Jun 20, 2016 heightened volatility was witnessed in Minerva Neurosciences Inc which led to swings in the share price. The shares opened for trading at $10.1 and hit $11.22 on the upside , eventually ending the session at $11.04, with a gain of 8.45% or 0.86 points. The heightened volatility saw the trading volume jump to 8,53,674 shares. The 52-week high of the share price is $15.84 and the company has a market cap of $308 M . The 52-week low of the share price is at $3.45.
Company has been under the radar of several Street Analysts.Minerva Neurosciences Inc is Resumed by Jefferies to Buy. The Rating was issued on May 12, 2016.
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. Its lead product candidate is MIN-101 a compound for the potential treatment of patients with schizophrenia. Its product pipeline also includes MIN-117 MIN-202 and MIN-301. MIN-101 is a compound it is developing for the treatment of patients with schizophrenia. MIN-117 is a compound for the potential treatment of patients suffering from major depressive disorder (MDD). MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen for the treatment of insomnia. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein for the treatment of Parkinson’s disease.